Trial Profile
A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin With or Without Sulfonylurea Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jun 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Saxagliptin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 04 Jun 2019 Results published in the Diabetes Care
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes